Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
- PMID: 23644932
- DOI: 10.1001/jama.2013.4997
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
Erratum in
- JAMA. 2013 Jul 10;310(2):208
Abstract
Importance: Oral supplementation with the Age-Related Eye Disease Study (AREDS) formulation (antioxidant vitamins C and E, beta carotene, and zinc) has been shown to reduce the risk of progression to advanced age-related macular degeneration (AMD). Observational data suggest that increased dietary intake of lutein + zeaxanthin (carotenoids), omega-3 long-chain polyunsaturated fatty acids (docosahexaenoic acid [DHA] + eicosapentaenoic acid [EPA]), or both might further reduce this risk.
Objectives: To determine whether adding lutein + zeaxanthin, DHA + EPA, or both to the AREDS formulation decreases the risk of developing advanced AMD and to evaluate the effect of eliminating beta carotene, lowering zinc doses, or both in the AREDS formulation.
Design, setting, and participants: The Age-Related Eye Disease Study 2 (AREDS2), a multicenter, randomized, double-masked, placebo-controlled phase 3 study with a 2 × 2 factorial design, conducted in 2006-2012 and enrolling 4203 participants aged 50 to 85 years at risk for progression to advanced AMD with bilateral large drusen or large drusen in 1 eye and advanced AMD in the fellow eye.
Interventions: Participants were randomized to receive lutein (10 mg) + zeaxanthin (2 mg), DHA (350 mg) + EPA (650 mg), lutein + zeaxanthin and DHA + EPA, or placebo. All participants were also asked to take the original AREDS formulation or accept a secondary randomization to 4 variations of the AREDS formulation, including elimination of beta carotene, lowering of zinc dose, or both.
Main outcomes and measures: Development of advanced AMD. The unit of analyses used was by eye.
Results: Median follow-up was 5 years, with 1940 study eyes (1608 participants) progressing to advanced AMD. Kaplan-Meier probabilities of progression to advanced AMD by 5 years were 31% (493 eyes [406 participants]) for placebo, 29% (468 eyes [399 participants]) for lutein + zeaxanthin, 31% (507 eyes [416 participants]) for DHA + EPA, and 30% (472 eyes [387 participants]) for lutein + zeaxanthin and DHA + EPA. Comparison with placebo in the primary analyses demonstrated no statistically significant reduction in progression to advanced AMD (hazard ratio [HR], 0.90 [98.7% CI, 0.76-1.07]; P = .12 for lutein + zeaxanthin; 0.97 [98.7% CI, 0.82-1.16]; P = .70 for DHA + EPA; 0.89 [98.7% CI, 0.75-1.06]; P = .10 for lutein + zeaxanthin and DHA + EPA). There was no apparent effect of beta carotene elimination or lower-dose zinc on progression to advanced AMD. More lung cancers were noted in the beta carotene vs no beta carotene group (23 [2.0%] vs 11 [0.9%], nominal P = .04), mostly in former smokers.
Conclusions and relevance: Addition of lutein + zeaxanthin, DHA + EPA, or both to the AREDS formulation in primary analyses did not further reduce risk of progression to advanced AMD. However, because of potential increased incidence of lung cancer in former smokers, lutein + zeaxanthin could be an appropriate carotenoid substitute in the AREDS formulation.
Trial registration: clinicaltrials.gov Identifier: NCT00345176.
Similar articles
-
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.JAMA Ophthalmol. 2014 Feb;132(2):142-9. doi: 10.1001/jamaophthalmol.2013.7376. JAMA Ophthalmol. 2014. PMID: 24310343 Free PMC article. Clinical Trial.
-
Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28.JAMA Ophthalmol. 2022 Jul 1;140(7):692-698. doi: 10.1001/jamaophthalmol.2022.1640. JAMA Ophthalmol. 2022. PMID: 35653117 Free PMC article. Clinical Trial.
-
Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.Cochrane Database Syst Rev. 2023 Sep 13;9(9):CD000254. doi: 10.1002/14651858.CD000254.pub5. Cochrane Database Syst Rev. 2023. PMID: 37702300 Free PMC article. Review.
-
The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1).Ophthalmology. 2012 Nov;119(11):2282-9. doi: 10.1016/j.ophtha.2012.05.027. Epub 2012 Jul 26. Ophthalmology. 2012. PMID: 22840421 Free PMC article. Clinical Trial.
-
Prevention and treatment of age-related macular degeneration: an update for pharmacists.Consult Pharm. 2013 Nov;28(11):723-37. doi: 10.4140/TCP.n.2013.723. Consult Pharm. 2013. PMID: 24217192 Review.
Cited by
-
Haemophilus influenzae Endophthalmitis Associated With Intravitreal Pegcetacoplan Injection.J Vitreoretin Dis. 2024 Aug 31:24741264241276594. doi: 10.1177/24741264241276594. Online ahead of print. J Vitreoretin Dis. 2024. PMID: 39554623 Free PMC article.
-
Protective effect of zinc against A2E-induced toxicity in ARPE-19 cells: Possible involvement of lysosomal acidification.Heliyon. 2024 Oct 11;10(21):e39100. doi: 10.1016/j.heliyon.2024.e39100. eCollection 2024 Nov 15. Heliyon. 2024. PMID: 39524844 Free PMC article.
-
Crocus sativus (saffron) and age-related macular degeneration.Med Hypothesis Discov Innov Ophthalmol. 2024 Oct 14;13(3):139-150. doi: 10.51329/mehdiophthal1505. eCollection 2024 Fall. Med Hypothesis Discov Innov Ophthalmol. 2024. PMID: 39507811 Free PMC article. Review.
-
Cigarette smoke extract induces ferroptosis in human retinal pigment epithelial cells.Heliyon. 2024 Sep 24;10(20):e38151. doi: 10.1016/j.heliyon.2024.e38151. eCollection 2024 Oct 30. Heliyon. 2024. PMID: 39498038 Free PMC article.
-
Quantifying the impact of disease severity changes on the burden of blindness: A global decomposition analysis.J Glob Health. 2024 Nov 1;14:04248. doi: 10.7189/jogh.14.04248. J Glob Health. 2024. PMID: 39485018 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials